A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients With Relapsed or Refractory Lymphomas
Phase of Trial: Phase I/II
Latest Information Update: 29 Sep 2018
At a glance
- Drugs RP 4010 (Primary)
- Indications Lymphoma
- Focus Adverse reactions
- Sponsors Rhizen Pharmaceuticals
- 14 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 14 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 May 2017 Status changed from not yet recruiting to recruiting.